Views & Analysis SMA Awareness Month: How pharma and digital solutions can im... Spinal Muscular Atrophy (SMA) is a rare disease affecting the motor nerve cells in the spinal cord.
News Avalyn seeks $300m from its IPO Pulmonary fibrosis drug developer Avalyn prices its IPO at around $300m, as Seaport and Hemab both target $180m-plus from their listings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
